Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Other Non Operating Income (2020 - 2022)

Terns Pharmaceuticals filings provide 3 years of Other Non Operating Income readings, the most recent being -$4000.0 for Q4 2022.

  • Quarterly Other Non Operating Income fell 140.0% to -$4000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$68000.0 through Dec 2022, down 270.0% year-over-year, with the annual reading at -$93000.0 for FY2025, 745.45% down from the prior year.
  • Other Non Operating Income hit -$4000.0 in Q4 2022 for Terns Pharmaceuticals, up from -$14000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $10.7 million in Q4 2020 and bottomed at -$387000.0 in Q3 2020.
  • Average Other Non Operating Income over 3 years is $889416.7, with a median of $4000.0 recorded in 2021.
  • Peak annual rise in Other Non Operating Income hit 130.77% in 2022, while the deepest fall reached 450.0% in 2022.
  • Terns Pharmaceuticals' Other Non Operating Income stood at $10.7 million in 2020, then crashed by 99.91% to $10000.0 in 2021, then tumbled by 140.0% to -$4000.0 in 2022.
  • Per Business Quant, the three most recent readings for TERN's Other Non Operating Income are -$4000.0 (Q4 2022), -$14000.0 (Q3 2022), and -$54000.0 (Q2 2022).